Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$1,640 Mln
P/E Ratio
--
P/B Ratio
0.5
Industry P/E
--
Debt to Equity
0
ROE
-0 %
ROCE
2.59 %
Div. Yield
0 %
Book Value
43.34
EPS
1.11
CFO
€1,145.47 Mln
EBITDA
€-407.72 Mln
Net Profit
€-469.02 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Galapagos NV - ADR
| -8.73 | -2.79 | 5.33 | -13.69 | -26.99 | -34.60 | -3.31 |
|
BSE Sensex
| 1.72 | 3.50 | 4.95 | 8.90 | 11.18 | 21.04 | 11.14 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|---|
|
Galapagos NV - ADR
| -32.13 | -8.40 | -19.50 | -44.30 | -52.14 | 125.45 | -2.14 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T... product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc.; and AbbVie S.à r.l. The company was incorporated in 1999 and is headquartered in Mechelen, Belgium. Address: Generaal De Wittelaan L11 A3, Mechelen, Belgium, 2800 Read more
CEO, Chairman, Interim Head of R&D
Dr. Paulus A. Stoffels M.D., Ph.D.
CEO, Chairman, Interim Head of R&D
Dr. Paulus A. Stoffels M.D., Ph.D.
Headquarters
Mechelen
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Galapagos NV - ADR stood at $ 4,136 Mln as on 31-Dec-24
The share price of Galapagos NV - ADR is $25.10 (NASDAQ) as of 22-Apr-2025 12:39 EDT. Galapagos NV - ADR has given a return of -26.99% in the last 3 years.
Galapagos NV - ADR has a market capitalisation of $ 1,640 Mln as on 21-Apr-2025. As per Value Research classification, it is a company.
Since, TTM earnings of Galapagos NV - ADR is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Galapagos NV - ADR and enter the required number of quantities and click on buy to purchase the shares of Galapagos NV - ADR.
Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc.; and AbbVie S.à r.l. The company was incorporated in 1999 and is headquartered in Mechelen, Belgium. Address: Generaal De Wittelaan L11 A3, Mechelen, Belgium, 2800
The CEO & director of Dr. Paulus A. Stoffels M.D., Ph.D.. is Galapagos NV - ADR, and CFO & Sr. VP is Dr. Paulus A. Stoffels M.D., Ph.D..
There is no promoter pledging in Galapagos NV - ADR.
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|
| Galapagos NV - ADR | Ratios |
|---|---|
|
Return on equity(%)
|
2.6
|
|
Operating margin(%)
|
-68.33
|
|
Net Margin(%)
|
26.88
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Galapagos NV - ADR was $0 Mln.
$0.46
(
